About Cell Design Labs
Cell Design Labs is a company based in San Francisco (United States) founded in 2016 was acquired by Gilead in December 2017. Cell Design Labs has raised $34.4 million across 1 funding round from investors including Gilead, Kleiner Perkins and Kite Pharma. Cell Design Labs operates in a competitive market with competitors including Jazz Pharmaceuticals, Celgene, C4 Therapeutics, Erasca and Revolution Medicines, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cell Design Labs
Cell Design Labs has successfully raised a total of $34.4M through 1 strategic funding round. The most recent funding activity was a Series A round of $34.4 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cell Design Labs
Cell Design Labs has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Gilead, Kleiner Perkins and Kite Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US focused VC firm
|
Locked | Locked | Locked | |
|
Venture capital firm investing in early-stage tech startups
|
Locked | Locked | Locked | |
|
Early- to growth-stage startups are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Cell Design Labs
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cell Design Labs
Investment portfolio details for Cell Design Labs
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cell Design Labs
Detailed financials for Cell Design Labs
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cell Design Labs Comparisons
Peer comparison for Cell Design Labs
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cell Design Labs
Cell Design Labs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Celgene, C4 Therapeutics, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for cancer and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
Detailed competitors of Cell Design Labs
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cell Design Labs
Complete news archive for Cell Design Labs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cell Design Labs
Cell Design Labs was founded in 2016.
Cell Design Labs is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Brian Atwood is the current CEO of Cell Design Labs.
Cell Design Labs is a funded company, having raised a total of $34.4M across 1 funding round to date.
Cell Design Labs was founded in 2016 in San Francisco, United States, and incubated at JLabs. Research from the University of California forms its basis, with operations centered on engineering T cells using chimeric antigen receptors or T cell receptors to address cancer. A portfolio of therapies is being built for hematologic and solid tumors, alongside partnerships with oncology firms for broader applications in devastating diseases.
Cell Design Labs's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Cell Design Labs has 5 investors. Key investors include Gilead, Kleiner Perkins, Kite Pharma, Mission Bay Capital, and Osage University Partners.